These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 8549013)

  • 1. The pathological implications of protein glycation.
    Brownlee M
    Clin Invest Med; 1995 Aug; 18(4):275-81. PubMed ID: 8549013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.
    Friedman EA
    Diabetes Care; 1999 Mar; 22 Suppl 2():B65-71. PubMed ID: 10097902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
    Booth AA; Khalifah RG; Hudson BG
    Biochem Biophys Res Commun; 1996 Mar; 220(1):113-9. PubMed ID: 8602828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing.
    Yan SF; Yan SD; Herold K; Ramsamy R; Schmidt AM
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):511-24, viii. PubMed ID: 16959583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
    Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycation endproducts: what is their relevance to diabetic complications?
    Ahmed N; Thornalley PJ
    Diabetes Obes Metab; 2007 May; 9(3):233-45. PubMed ID: 17391149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible link of food-derived advanced glycation end products (AGEs) to the development of diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2008 Dec; 71(6):876-8. PubMed ID: 18783891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced glycation end product (age) inhibitors and their therapeutic implications in diseases.
    Takeuchi M; Yamagishi S; Iwaki M; Nakamura K; Imaizumi T
    Int J Clin Pharmacol Res; 2004; 24(2-3):95-101. PubMed ID: 15689055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications.
    Saraswat M; Reddy PY; Muthenna P; Reddy GB
    Br J Nutr; 2009 Jun; 101(11):1714-21. PubMed ID: 18986599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-enzymatic glycation of proteins: a cause for complications in diabetes.
    Nawale RB; Mourya VK; Bhise SB
    Indian J Biochem Biophys; 2006 Dec; 43(6):337-44. PubMed ID: 17285797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
    Yamagishi S; Nakamura K; Matsui T; Ueda S; Noda Y; Imaizumi T
    Cardiovasc Ther; 2008; 26(1):50-8. PubMed ID: 18466420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy.
    Stitt AW; Moore JE; Sharkey JA; Murphy G; Simpson DA; Bucala R; Vlassara H; Archer DB
    Invest Ophthalmol Vis Sci; 1998 Dec; 39(13):2517-23. PubMed ID: 9856760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycated proteins in diabetes.
    Furth AJ
    Br J Biomed Sci; 1997 Sep; 54(3):192-200. PubMed ID: 9499597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
    Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
    Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications.
    Ceriello A
    Diabetes Nutr Metab; 1999 Feb; 12(1):42-6. PubMed ID: 10517306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes.
    Rojas A; Morales MA
    Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylglyoxal: possible link between hyperglycaemia and immune suppression?
    Price CL; Knight SC
    Trends Endocrinol Metab; 2009 Sep; 20(7):312-7. PubMed ID: 19709901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation end-products and the progress of diabetic vascular complications.
    Jakus V; Rietbrock N
    Physiol Res; 2004; 53(2):131-42. PubMed ID: 15046548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.